New Potential Agents for Malignant Melanoma Treatment—Most Recent Studies 2020–2022

Malignant melanoma (MM) is the most lethal skin cancer. Despite a 4% reduction in mortality over the past few years, an increasing number of new diagnosed cases appear each year. Long-term therapy and the development of resistance to the drugs used drive the search for more and more new agents with...

Descripción completa

Detalles Bibliográficos
Autores principales: Kozyra, Paweł, Krasowska, Danuta, Pitucha, Monika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9180979/
https://www.ncbi.nlm.nih.gov/pubmed/35682764
http://dx.doi.org/10.3390/ijms23116084
_version_ 1784723653914525696
author Kozyra, Paweł
Krasowska, Danuta
Pitucha, Monika
author_facet Kozyra, Paweł
Krasowska, Danuta
Pitucha, Monika
author_sort Kozyra, Paweł
collection PubMed
description Malignant melanoma (MM) is the most lethal skin cancer. Despite a 4% reduction in mortality over the past few years, an increasing number of new diagnosed cases appear each year. Long-term therapy and the development of resistance to the drugs used drive the search for more and more new agents with anti-melanoma activity. This review focuses on the most recent synthesized anti-melanoma agents from 2020–2022. For selected agents, apart from the analysis of biological activity, the structure–activity relationship (SAR) is also discussed. To the best of our knowledge, the following literature review delivers the latest achievements in the field of new anti-melanoma agents.
format Online
Article
Text
id pubmed-9180979
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91809792022-06-10 New Potential Agents for Malignant Melanoma Treatment—Most Recent Studies 2020–2022 Kozyra, Paweł Krasowska, Danuta Pitucha, Monika Int J Mol Sci Review Malignant melanoma (MM) is the most lethal skin cancer. Despite a 4% reduction in mortality over the past few years, an increasing number of new diagnosed cases appear each year. Long-term therapy and the development of resistance to the drugs used drive the search for more and more new agents with anti-melanoma activity. This review focuses on the most recent synthesized anti-melanoma agents from 2020–2022. For selected agents, apart from the analysis of biological activity, the structure–activity relationship (SAR) is also discussed. To the best of our knowledge, the following literature review delivers the latest achievements in the field of new anti-melanoma agents. MDPI 2022-05-29 /pmc/articles/PMC9180979/ /pubmed/35682764 http://dx.doi.org/10.3390/ijms23116084 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Kozyra, Paweł
Krasowska, Danuta
Pitucha, Monika
New Potential Agents for Malignant Melanoma Treatment—Most Recent Studies 2020–2022
title New Potential Agents for Malignant Melanoma Treatment—Most Recent Studies 2020–2022
title_full New Potential Agents for Malignant Melanoma Treatment—Most Recent Studies 2020–2022
title_fullStr New Potential Agents for Malignant Melanoma Treatment—Most Recent Studies 2020–2022
title_full_unstemmed New Potential Agents for Malignant Melanoma Treatment—Most Recent Studies 2020–2022
title_short New Potential Agents for Malignant Melanoma Treatment—Most Recent Studies 2020–2022
title_sort new potential agents for malignant melanoma treatment—most recent studies 2020–2022
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9180979/
https://www.ncbi.nlm.nih.gov/pubmed/35682764
http://dx.doi.org/10.3390/ijms23116084
work_keys_str_mv AT kozyrapaweł newpotentialagentsformalignantmelanomatreatmentmostrecentstudies20202022
AT krasowskadanuta newpotentialagentsformalignantmelanomatreatmentmostrecentstudies20202022
AT pituchamonika newpotentialagentsformalignantmelanomatreatmentmostrecentstudies20202022

Ejemplares similares